Activity of twelve second-line antimicrobial agents against Mycobacterium tuberculosis in Taiwan

Journal of Chemotherapy

Volumn 20, Issue 2, 2008, Pages 202-207

  Lu, Po Liang ^a   Peng, Chien Fang ^a   Hwang, Jhi Jhih ^a   Chen, Yen Hsu ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Multidrug resistance; Second line drugs; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESEARCH; HUMAN; INFECTION CONTROL; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; TAIWAN;

EID: 44849085205     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.2.202     Document Type: Article

References (36)

1. Murray CJ, Salomon JA. Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci U S A. 1998; 95 (23): 13881-13886.
2. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000; 283 (19): 2537-2545.
3. Center for Disease Control. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR. 2006; 55 (11):301-305.
4. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC): The Hague: Tuberculosis Coalition for Technical Assistance 2006.
5. Lu PL, Lee YW, Peng CF, Tsai JJ, Chen YH, Hwang KP, et al. The decline of high drug resistance rate of pulmonary Mycobacterium tuberculosis isolates from a southern Taiwan medical centre, 1996-2000. Int J Antimicrob Agents. 2003; 21 (3): 239-243.
6. Wang PD, Lin RS. Drug-resistant tuberculosis in Taipei, 1996-1999. Am J Infect Control. 2001;29 (1): 41-47.
7. WHO CD. Anti-tuberculosis drug resistance in the world. Report No. 2. Prevalence and trends. Geneva; World Health Organization 2000.
8. Inderlied CB NKA. Antimycobacterial agents: in vitro susceptibility testing, spectra of activity, mechanisms of action and resistance, and assays for activity in biologic fluids. In: V L, ed. Antibiotics in Laboratory Medicine. Baltimore, Md: The Williams & Wilkins Co. 1996.
9. National Committee for Clinical Laboratory Standards. Antimycobacterial susceptibility testing for Mycobacterium tuberculosis; Tentative standard M24-T. Villanova, Pa.: National Committee for Clinical Laboratory Standards 1995.
10. National Committee for Clinical Laboratory Standards. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic Actinomycetes. Tentative standard M24-T2. . Wayne, PA: National Committee for Clinical Laboratory Standards 2000.
11. Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis. 2000; 31 (5): 1209-1215.
12. WHO. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Weekly epidemiological record / Health Section of the Secretariat of the League of Nations. 2006; 81 (45): 430-432.
13. Pfyffer GE, Bonato DA, Ebrahimzadeh A, Gross W, Hotaling J, Kornblum J, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol. 1999; 37 (10): 3179-3186.
14. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J. 2007; 29 (3): 423-427.
15. Masjedi MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, Zarifi AZ, et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis. 2006; 43 (7): 841-847.
16. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368 (9547): 1575-1580.
17. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994; 263 (5144): 227-230.
18. Kruuner A, Jureen P, Levina K, Ghebremichael S, Hoffner S. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2003; 47 (9): 2971-2973.
19. Hoffner SE, Kallenius G. Susceptibility of streptomycin-resistant Mycobacterium tuberculosis strains to amikacin. Eur J Clin Microbiol Infect Dis. 1988; 7 (2): 188-190.
20. McClatchy JK, Kanes W, Davidson PT, Moulding TS. Cross-resistance in Mycobacterium tuberculosis to kanamycin, capreomycin and viomycin. Tubercle. 1977; 58 (1): 29-34.
21. Palmero D RV, Ambroggi M, Natiello M, Barrera L, Capone L et al. Emergence of initial multidrug-resistant tuberculosis among HIV negative patients at a referral hospital in Buenos Aires, Argentina. Am J Respir Crit Care Med. 2002; 165 (8): supp: A18 (abstract).
22. Hoffner SE, Gezelius L, Olsson-Liljequist B. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 1997; 40 (6): 885-888.
23. Tupasi TE, Quelapio MI, Orillaza RB, Alcantara C, Mira NR, Abeleda MR, et al. DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed. Tuberculosis (Edinb). 2003; 83 (1-3): 52-58.
24. Yu MC, Suo J, Lin TP, Luh KT. In vitro activity of ofloxacin against Mycobacterium tuberculosis. J Formos Med Assoc. 1997; 96 (1): 13-16.
25. Sheng WH, Chen YC, Wang JT, Chang SC, Luh KT, Hsieh WC. Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan. Diagn Microbiol Infect Dis. 2002 43(2):141-7.
26. Rodriguez JC, Ruiz M, Climent A, Royo G. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents. 2001; 17 (3): 229-231.
27. Vacher S, Pellegrin JL, Leblanc F, Fourche J, Maugein J. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin. J Antimicrob Chemother. 1999; 44 (5): 647-652.
28. Abate G, Miorner H. Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol. J Antimicrob Chemother. 1998; 42 (6): 735-740.
29. Cook PJ, Andrews JM, Woodcock J, Wise R, Honeybourne D. Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax. 1994; 49 (11): 1134-1138.
30. Donald PR, Sirgel FA, Venter A, Parkin DP, Van de Wal BW, Barendse A, et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand J Infect Dis. 2001; 33 (6): 466-469.
31. Cavalieri SJ, Biehle JR, Sanders WE, Jr. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995; 39 (7): 1542-1545.
32. Huang TS, Lee SS, Tu HZ, Huang WK, Chen YS, Huang CK, et al. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob Agents Chemother. 2003; 47 (11): 3672-3673.
33. Hwang HY, Chang CY, Chang LL, Chang SF, Chang YH, Chen YJ. Characterization of rifampicin-resistant Mycobacterium tuberculosis in Taiwan. J Med Microbiol. 2003; 52 (Pt 3): 239-245.
34. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005; 25 (3): 564-569.
35. Fattorini L, Iona E, Ricci ML, Thoresen OF, Orru G, Oggioni MR, et al. Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis. Microb Drug Resist. 1999; 5 (4): 265-270.
36. Reddy VM, O'Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother. 1999; 43 (5): 615-623.